Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Regadenoson

FDA-approved product (solution, intravenous), marketed as Lexiscan, Regadenoson.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Regadenoson
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Myocardial Perfusion Imaging

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other cardiac preparations
FDA pharmacologic class
Adenosine Receptor Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli48.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Regadenoson in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Regadenoson with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

    NCT07761910 · start 2026-09

    Registered record
    Registry ID
    NCT07761910
    Conditions
    Non Small Cell Lung Cancer; Cardiotoxicity; Locally Advanced Non-Small Cell Lung Cancer; Radiation Therapy
    Interventions
    PET/CT 18F-Flurpiridaz Rest/Stress Test; Coronary CT Angiography (CCTA); 18F-Flurpiridaz
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-09
    Completion
    2027-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; Cardiotoxicity; Locally Advanced Non-Small Cell Lung Cancer; Radiation Therapy
    InterventionPET/CT 18F-Flurpiridaz Rest/Stress Test; Coronary CT Angiography (CCTA); 18F-Flurpiridaz
    PhasePhase 2
    Registry statusRecruiting

  • Quantitative Analysis of Cardiac Muscle Perfusion

    NCT07548879 · start 2026-06-01

    Registered record
    Registry ID
    NCT07548879
    Conditions
    Myocardial Ischemia
    Interventions
    Magnetic Resonance Imaging with Contrast
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-06-01
    Completion
    2029-12-30
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Ischemia
    InterventionMagnetic Resonance Imaging with Contrast
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy

    NCT06814587 · start 2024-07-01

    Registered record
    Registry ID
    NCT06814587
    Conditions
    Coronary Artery Disease; Coronary Artery Bypass Graft (CABG)
    Interventions
    Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI); [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET); SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-07-01
    Completion
    2027-06-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Coronary Artery Bypass Graft (CABG)
    InterventionHyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI); [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET); SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
    PhaseNot recorded
    Registry statusRecruiting

  • Cardiac Magnetic Resonance Stress-perfusion Study in Patinets with Fontan Circulation

    NCT06735521 · start 2024-04-15

    Registered record
    Registry ID
    NCT06735521
    Conditions
    Univentricular Heart; Microvascular Dysfunction; Heart Failure; Magnetic Resonance
    Interventions
    Cardiac magnetic resonance stress-perfusion
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-04-15
    Completion
    2025-09-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUniventricular Heart; Microvascular Dysfunction; Heart Failure; Magnetic Resonance
    InterventionCardiac magnetic resonance stress-perfusion
    PhaseNot recorded
    Registry statusRecruiting

  • Treat COVID-19 Patients With Regadenoson

    NCT04606069 · start 2021-05-06

    Registered record
    Registry ID
    NCT04606069
    Conditions
    COVID-19; Lung Inflammation
    Interventions
    Regadenoson; Placebo Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2021-05-06
    Completion
    2023-04-24
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19; Lung Inflammation
    InterventionRegadenoson; Placebo Control
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging

    NCT05081115 · start 2021-04-01

    Registered record
    Registry ID
    NCT05081115
    Conditions
    Coronary Artery Disease; Heart Failure; Hypertrophic Cardiomyopathy; Congenital Heart Disease; Valvular Heart Disease; Post-chest Radio/Chemiotherapy; Heart Transplantation
    Interventions
    ABCDE-Stress Echo; SE diastolic assessment; SE Right ventricular function assessment; SE in heart donors
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-04-01
    Completion
    2030-12-31
    Enrolment
    10,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Heart Failure; Hypertrophic Cardiomyopathy; Congenital Heart Disease +3 more
    InterventionABCDE-Stress Echo; SE diastolic assessment; SE Right ventricular function assessment; SE in heart donors
    PhaseNot recorded
    Registry statusRecruiting

  • Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System

    NCT04521569 · start 2020-06-22

    Registered record
    Registry ID
    NCT04521569
    Conditions
    Lung Transplant
    Interventions
    Regadenoson; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2020-06-22
    Completion
    2024-07-31
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Transplant
    InterventionRegadenoson; Placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status

    NCT04475094 · start 2019-12-23

    Registered record
    Registry ID
    NCT04475094
    Conditions
    Coronary Artery Disease
    Interventions
    Rubidium-82; Seattle Angina Questionnaire-7; Rose Dyspnea Scale
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-12-23
    Completion
    2021-12-31
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionRubidium-82; Seattle Angina Questionnaire-7; Rose Dyspnea Scale
    PhaseNot recorded
    Registry statusUnknown

  • Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

    NCT03971734 · start 2019-12-06

    Registered record
    Registry ID
    NCT03971734
    Conditions
    High Grade Glioma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Glioblastoma
    Interventions
    Regadenoson 0.05mg; Regadensoson 0.1mg; Regadensoson 0.2mg; Regadensoson 0.4mg; Regadensoson 0.7mg; Regadensoson 1.0mg; Regadensoson 1.4mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2019-12-06
    Completion
    2023-10-02
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Grade Glioma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Glioblastoma
    InterventionRegadenoson 0.05mg; Regadensoson 0.1mg; Regadensoson 0.2mg; Regadensoson 0.4mg +3 more
    PhasePhase 1
    Registry statusTerminated

  • Allograft Dysfunction in Heart Transplant

    NCT03102125 · start 2019-10-01

    Registered record
    Registry ID
    NCT03102125
    Conditions
    Heart Transplant Failure and Rejection
    Interventions
    Regadenoson
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2019-10-01
    Completion
    2027-01-02
    Enrolment
    376

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Transplant Failure and Rejection
    InterventionRegadenoson
    PhasePhase 4
    Registry statusRecruiting

  • The Evaluation of the Roles of New Cardiac Imaging in Patients With Chest Pain

    NCT03800862 · start 2019-03-27

    Registered record
    Registry ID
    NCT03800862
    Conditions
    Cardiology; Radiology; Stenoses
    Interventions
    CT-FFR and CTP
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2019-03-27
    Completion
    2022-10-27
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiology; Radiology; Stenoses
    InterventionCT-FFR and CTP
    PhaseNot recorded
    Registry statusTerminated

  • Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome

    NCT03449888 · start 2018-07-01

    Registered record
    Registry ID
    NCT03449888
    Conditions
    Veterans Referred to the St. Louis VAMC Stress Tes
    Interventions
    Regadenoson myocardial perfusion imaging stress test; Arm exercise electrocardiographic stress test; Treadmill electrocardiographic stress test; Coronary artery calcium score and cardiac computed tomographic angiography
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2018-07-01
    Completion
    2021-02-05
    Enrolment
    133

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVeterans Referred to the St. Louis VAMC Stress Tes
    InterventionRegadenoson myocardial perfusion imaging stress test; Arm exercise electrocardiographic stress test; Treadmill electrocardiographic stress test; Coronary artery calcium score and cardiac computed tomographic angiography
    PhaseNot recorded
    Registry statusTerminated

  • Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer

    NCT03505736 · start 2018-06-21

    Registered record
    Registry ID
    NCT03505736
    Conditions
    Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Premenopausal; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8
    Interventions
    Adenosine; Magnetic Resonance Imaging; Regadenoson; Stress Management Therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-06-21
    Completion
    2020-03-05
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8 +17 more
    InterventionAdenosine; Magnetic Resonance Imaging; Regadenoson; Stress Management Therapy
    PhaseNot recorded
    Registry statusCompleted

  • An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

    NCT03354273 · start 2018-06-05

    Registered record
    Registry ID
    NCT03354273
    Conditions
    Coronary Artery Disease (CAD)
    Interventions
    PET MPI; SPECT MPI; Pharmacological stress agents
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-06-05
    Completion
    2022-05-05
    Enrolment
    730

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease (CAD)
    InterventionPET MPI; SPECT MPI; Pharmacological stress agents
    PhasePhase 3
    Registry statusCompleted

  • Whole-Heart Myocardial Blood Flow Quantification Using MRI

    NCT03064295 · start 2018-03-01

    Registered record
    Registry ID
    NCT03064295
    Conditions
    Coronary Artery Disease; Coronary Microvascular Disease
    Interventions
    Myocardial Perfusion Cardiac MRI.; Contrast; Pharmacologic Stress Agent
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-03-01
    Completion
    2025-01-01
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Coronary Microvascular Disease
    InterventionMyocardial Perfusion Cardiac MRI.; Contrast; Pharmacologic Stress Agent
    PhaseNot recorded
    Registry statusUnknown